US/Europe Event-Driven Analyst

John DeMasi

CFA, CPA (New York State, status: inactive) with 20+ years on buyside (PM & analyst) at numerous hedge funds and proprietary trading desks in NYC and London, covering North American and European event driven investments.

Bristol Myers Squib – Reaffirming Its View on Celgene Corp

Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated

Celgene Acquisition by Bristol-Myers Squibb: A Call to Arbs

Event-Driven

<p><a href="https://www.smartkarma.com/entities/1133" target="_blank" data-smartkarma-citation="entities:1133:1">Bristol Myers Squibb Co (BMY US)</a> announced <a href="https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2019/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results/default.aspx" target="_blank">earnings</a> for 4Q18 this morning followed by a <a href="https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;referrer=https%3A%2F%2Fwww.bms.com%2Finvestors.html&amp;eventid=1868013&amp;sessionid=1&amp;key=41E2C4F8CF3E6AC564098D206ECDC05B&amp;regTag=&amp;sourcepage=register" target="_blank">conference call</a>. Most metrics beat street expectations but the withdrawal of its application for Opdivo + low-dose Yervoy for first-line (NSCLC) lung cancer patients with high tumor mutation burdens after discussions with the FDA weighed on shares of BMY today. But for arbs who have the CELG/BMY spread set up, the positive comments on the <a href="https://www.smartkarma.com/entities/7410" target="_blank" data-smartkarma-citation="entities:7410:1">Celgene Corp (CELG US)</a> acquisition provided further assurance of BMY’s commitment to the deal.</p>

Bristol Myers Squibb Co (BMY US) announced earnings for 4Q18 this morning followed by a conference call. Most metrics beat street expectations but the withdrawal of its application for Opdivo + low-dose Yervoy for first-line (NSCLC) lung cancer patients with high tumor mutation burdens after discussions with the FDA weighed on shares of BMY today. But for arbs who have the CELG/BMY spread set up, the positive comments on the Celgene Corp (CELG US) acquisition provided further assurance of BMY’s commitment to the deal.

Bristol-Myers Beats the Drum for Celgene in 4Q18 Earnings Call